Hologic’s $18.3 billion private takeover deal by Blackstone and TPG is nearing completion, with shareholders and China’s SAMR having approved the acquisition. The deal offers $76 per share in cash plus a contingent value right, representing a significant premium to the closing price before media reports emerged. Despite missing Q1 fiscal 2026 analyst forecasts, the limited upside for shareholders due to the proximity of the buyout and the stock’s current valuation suggests investors might consider exiting their positions.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
How to Play Hologic Stock Post Q1 Earnings and Progress on Buyout?
Hologic’s $18.3 billion private takeover deal by Blackstone and TPG is nearing completion, with shareholders and China’s SAMR having approved the acquisition. The deal offers $76 per share in cash plus a contingent value right, representing a significant premium to the closing price before media reports emerged. Despite missing Q1 fiscal 2026 analyst forecasts, the limited upside for shareholders due to the proximity of the buyout and the stock’s current valuation suggests investors might consider exiting their positions.